NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY
Livia Lontai 1
Lorant Gonczi 1
Fruzsina Balogh 1
Nora Komlodi 1
Tamás Resál 2
Klaudia Farkas 2
Tamás Molnár 2
Pal Miheller 2
Petra Anna Golovics 3
Eszter Schäfer 3
Tamás Szamosi 3
Ákos Iliás 3
Peter L Lakatos 4
1 Semmelweis University, Budapest, Hungary
2 University of Szeged, Szeged, Hungary
3 Hungarian Defence Forces Medical Centre, Budapest, Hungary
4 McGill University Health Center, Montreal, Canada
Session
IBD (Posters)
Conference
UEG Week Vienna 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]